MedTrace Logo

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2019-06-19

No results posted yet for this study

Summary

Inflammatory bowel disease (IBD) patients under the age of 50 can have a greater risk than the general population above age 50. IBD patient are commonly treated with immunosuppression that increases the risk for Herpes Zoster. A new HZ vaccine is available that could decrease the risk of HZ in IBD patients.

Conditions

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Freddy Caldera, DO · University of Wisconsin School of Medicine

Eligibility

Min Age
35 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553472 on ClinicalTrials.gov